Casdin Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Casdin Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000,000	Closed	-$13.9M	–	41
2022 Q1	$13.9M	Hold	1,000,000	–	–	0.62%	30
2021 Q4	$28.1M	Sell	1,000,000 -440,000	-31%	-$13.5M	0.79%	31
2021 Q3	$48.9M	Hold	1,440,000	–	–	1.22%	29
2021 Q2	$58.8M	Buy	1,440,000 +290,000	+25%	+$11.3M	1.49%	21
2021 Q1	$46.3M	Buy	1,150,000 +436,875	+61%	+$23.6M	1.38%	18
2020 Q4	$42.2M	Hold	713,125	–	–	1.25%	20
2020 Q3	$34.7M	Hold	713,125	–	–	1.55%	21
2020 Q2	$34.5M	Sell	713,125 -80,000	-10%	-$2.92M	2.04%	16
2020 Q1	$22M	Buy	793,125 +330,000	+71%	+$9.2M	2.34%	17
2019 Q4	$13.9M	Hold	463,125	–	–	1.27%	25
2019 Q3	$14.3M	Hold	463,125	–	–	1.48%	22
2019 Q2	$20.1M	Buy	+463,125	New	+$20.5M	1.88%	18

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Casdin Capital's ADPT Position: Q2 2022 in Review

Casdin Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 1,000,000 shares — an estimated $13.9M sold.

Casdin Capital first reported a position in ADPT in Q2 2019 and held it in 12 quarters. The position peaked at $58.8M in Q2 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

Casdin Capital reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
Casdin Capital sold 1,000,000 Adaptive Biotechnologies shares in Q2 2022, an estimated $13.9M.
Casdin Capital first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 12 quarters.
Casdin Capital's Adaptive Biotechnologies position peaked at $58.8M in Q2 2021.
209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.